Insights & news

European Commission Starts Construction of European Health Union

  • 12/11/2020
  • Articles

On 11 November 2020, the European Commission (the Commission) unveiled a series of proposals to start the development of the European Health Union (see, attached press release). Drawing lessons from the current fight against Covid-19, the Commission wants to strengthen the EU’s health security framework, reinforce the crisis preparedness and response role of EU agencies and increase coordination at EU level. As health is largely a national competence, the Commission’s proposals are likely to meet with resistance from Member States. At the same time, the fragmented response to the corona virus has shown that health policy may benefit from increased transnational powers in a few selected areas. The Commission’s Communication entitled “Building a European Health Union: Reinforcing the EU’s Resilience for Cross-border Health Threats” (the Communication) shows how the Commission seeks to move in that direction (see, attachment).
 
The Communication tackles the following policy areas and puts forward distinct proposals for each of them. 

  • Enforcing coordinated response at the EU level 

The Commission will reinforce the existing institutional architecture which consists of the EU Health Security Committee, the Early Warning and Response System and the EU Integrated Political Crisis Response. Against this backdrop, the Commission has already proposed to expand the powers of the European Centre for Disease Prevention and Control (ECDC) whose work will feed into the decisions of these other entities. The Commission will also propose a system for the EU recognition of an emergency situation and for advice on response measures. 

  • Medical countermeasures  

This category captures measures that apply to medicines (including vaccines), medical devices, personal protective equipment, testing material and kits, and laboratory equipment. First, the Commission will strengthen the existing Joint Procurement Agreement by adopting a range of measures, including an exclusivity approach that averts internal competition between the European Commission and Member States or among Member States. The Commission also envisages the participation of third countries. Second, the Commission wants to have the European Medicines Agency (EMA) take charge of medicine shortages by building on existing structures within EMA or involving EMA (see e.g., Van Bael & Bellis Life Sciences News Alert of 9 June 2020). But the Commission will also create new, EMA-hosted bodies. Concretely, the Commission envisages an array of improved or new structures, including an EU Executive Steering Group on shortages; an EU Executive Steering Group on medical devices; an EMA Emergency Task Force; EMA expert panels on high risk medical devices; enhanced EU clinical trials infrastructure; and a vaccine monitoring platform. 

  • Preparedness, response planning and reporting  

Central to the Commission’s proposed action is the adoption of a binding EU health crisis/pandemic preparedness and response plan which in turn will involve a range of steps with a significant role for the Member States and for the ECDC. 

  • Epidemiological surveillance 

The Commission wants to create a new epidemiological surveillance system which relies on artificial intelligence and other tools for modelling and risk assessment. Additionally, it will expand the access of the ECDC to health data as part of the emerging European Health Data Space. 

  • Laboratory findings, testing and contact tracing 

The Commission has an ambitious plan to establish networks of both EU reference testing laboratories and transfusion, transplantation and medically assisted reproduction services. In addition, the Commission also contemplates the creation of an automated contact tracing system. 

  • Early warning and risk assessment capacity 

The Commission will seek to establish a new risk assessment framework for all health hazards that will also prepare response measures. 

  • International cooperation 

The Commission and the relevant agencies will continue to work with international stakeholders and partner countries.

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 27/11/2020
    • Articles

    European Commission Fines Cephalon and Teva On Account of "Pay-for-Delay" Patent Settlement Agreement

    On 26 November 2020, the European Commission (the Commission) brought to an end a long running competition case by finding against Cephalon and Teva on account of a “pay-for-delay” patent settlement agreement involving modafinil, the active substance of a sleeping disorder medicine (see, attached Commission press release).

    Read more
    • 26/11/2020
    • Articles

    European Commission Presents Pharmaceutical Strategy for Europe

    On 25 November 2020, the European Commission (the Commission) unveiled its Pharmaceutical Strategy for Europe (PSE), a wide-ranging document that discusses a series of broad policy statements, tentative considerations and concrete measures to tackle the many challenges faced by the pharmaceutical sector and its diverse stakeholders (see, attached Commission Communication (2020) 761 final; Commission press release; and Commission Q&A). The announcement follows an extensive period of consultation, study and preparation (see, Van Bael & Bellis Life Sciences News Alerts of 20 October 2020; 12 August 2020; 17 June 2020; 3 June 2020; and 28 May 2020).

    Read more
    • 25/11/2020
    • Articles

    Potential Covid-19 Vaccine Supplier Moderna Sixth Contract Partner of European Commission

    On 24 November 2020, European Commission President von der Leyen released a statement announcing that she would approve a sixth agreement with a supplier of a potential Covid-19 vaccine (see, attachment). The Commission’s new contract partner is Moderna. Under the agreement, the Commission will have the right to buy up to 160 million doses of the vaccine, if and when that product obtains a marketing authorisation from the European Medicines Agency. In recent days, the Commission announced similar deals with CureVac (see, Van Bael & Bellis Life Sciences News Alert of 17 November 2020) and with BioNTech and Pfizer (see, Van Bael & Bellis Life Sciences News Alert of 12 November 2020). The Commission President suggested that a seventh agreement is being negotiated which paves the way for the creation in Europe of “one of the most comprehensive COVID-19 vaccine portfolios in the world”.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *